Cost-Effectiveness Analyses of Natalizumab (Tysabri ® ) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

Author： Gani Ray  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.26, Iss.7, 2008-01, pp. : 617-627

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-Analysis of Relapsing-Remitting Multiple Sclerosis in Italy after the Introduction of New Disease-Modifying Agents

By Russo P.  

Clinical Drug Investigation, Vol. 24, Iss. 7, 2004-01 ,pp. : 409-420

Adis International

Access to resources Recommend Favorite

The Cost of Multiple Sclerosis and the Cost Effectiveness of Disease-Modifying Agents in its Treatment

By Phillips C.J.  

CNS Drugs, Vol. 18, Iss. 9, 2004-01 ,pp. : 561-574

Adis International

Access to resources Recommend Favorite

Long-Term Cost Effectiveness of Interferon- -1a in the Treatment of Relapsing-Remitting Multiple Sclerosis: An Econometric Model

By Lepen C.  

Clinical Drug Investigation, Vol. 23, Iss. 9, 2003-01 ,pp. : 571-581

Adis International

Access to resources Recommend Favorite

Comparative Assessment of Immunomodulating Therapies for Relapsing-Remitting Multiple Sclerosis

By Khan O.   Zabad R.   Caon C.   Zvartau-Hind M.   Tselis A.   Lisak R.  

CNS Drugs, Vol. 16, Iss. 8, 2002-01 ,pp. : 563-578

Adis International

Access to resources Recommend Favorite

Natalizumab Modifies Catecholamines Levels Present in Patients with Relapsing- Remitting Multiple Sclerosis

By  

Current Pharmaceutical Design, Vol. 22, Iss. 31, 2016-09 ,pp. : 4876-4880

Bentham Science Publishers

Access to resources Recommend Favorite